Bortezomib reinduction chemotherapy in high‐risk ALL in first relapse: a report from the Children's Oncology Group

Summary While survival in paediatric acute lymphoblastic leukaemia (ALL) is excellent, survival following relapse is poor. Previous studies suggest proteasome inhibition with chemotherapy improves relapse ALL response rates. This phase 2 Children's Oncology Group study tested the hypothesis tha...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	British journal of haematology Ročník 186; číslo 2; s. 274 - 285
Hlavní autori:	Horton, Terzah M., Whitlock, James A., Lu, Xiaomin, O'Brien, Maureen M., Borowitz, Michael J., Devidas, Meenakshi, Raetz, Elizabeth A., Brown, Patrick A., Carroll, William L., Hunger, Stephen P.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Blackwell Publishing Ltd 01.07.2019
Predmet:	acute lymphoblastic leukaemia Acute lymphoblastic leukemia acute lymphocytic leukaemia Adolescent Adult Bortezomib Bortezomib - administration & dosage Bortezomib - adverse effects Chemotherapy Child Child, Preschool Children Clinical trials Diagnosis Disease-Free Survival Female Hematology Humans Infant Leukemia Lymphoma Male Minimal residual disease Neoplasm, Residual Oncology paediatric leukaemia Precursor Cell Lymphoblastic Leukemia-Lymphoma - blood Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor Cell Lymphoblastic Leukemia-Lymphoma - mortality proteasome inhibition Proteasome inhibitors Recurrence Survival Rate Time Factors proteasome inhibition acute lymphocytic leukaemia minimal residual disease acute lymphoblastic leukaemia paediatric leukaemia
ISSN:	0007-1048, 1365-2141, 1365-2141
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!